HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate Appropriators Press FDA On Acetaminophen Dosing, Pass On Expanding Drug Recall Authority

Executive Summary

Senate Appropriations Committee has bills for federal agencies’ FY2021 budgets. The committee, which also published each subcommittee’s report accompanying its appropriation legislation, has not scheduled hearings to vote on the bills.

You may also be interested in...



Temporary Funding For US Agencies Delays $5M For FDA’s Cannabidiols Regulatory Pathway Work

Senate on 29 September was expected to a pass a CR the House passed a week earlier to fund FDA and other federal departments and agencies through 11 December.

Support To Grant US FDA Authority To Order Recalls Of All Drugs Grows With Bill Introduced In Senate

Sen. Gary Peters says FDA should have the authority because relying on drug marketers to voluntarily recall products the agency has deemed unsafe isn’t sufficient to protect public health. He notes that manufacturers of OTC hand sanitizers imported from Mexico and found to contain methanol haven’t cooperated with the FDA on recalling the products.

US GAO Review Of FDA’s OTC Drug Oversight Signals Waiting For Monograph Reform Benefits

Benefits of OTC monograph reform legislation passed in March likely will take at least several years, according to GAO report to Congress. It notes the FDA still is analyzing the legislation and it may need two years to add and train staff.

Related Content

Topics

UsernamePublicRestriction

Register

OM013195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel